Skip to main content

Table 6 The frequencies of antifungal usage in patients from 2013 to 2017

From: Surveillance study of the prevalence, species distribution, antifungal susceptibility, risk factors and mortality of invasive candidiasis in a tertiary teaching hospital in Southwest China

 Antifungal agentPatients n (%)c
Total (n = 243)2013 (n = 20)2014 (n = 29)2015 (n = 44)2016 (n = 74)2017 (n = 76)
 Amphotericin B(i.v.)49 (20.2)6(30.0%)5 (17.2)13 (29.5)17 (23.0)8 (10.5)
 Fluconazolea(i.v.)122 (52.8)11 (55.0%)20 (69.0)19 (43.2)30 (40.5)42 (55.3)
 Voriconazole(i.v.)84 (34.6)8 (40.0)10 (34.5)15 (34.1)27 (36.5)24 (31.6)
 otherb20(13.3)00015(20.3)5(6.5)
  1. i.v. intravenous
  2. aC. krusei is excluded
  3. bother including caspofungin (intravenous) and itraconazole (oral)
  4. cSome patients used more than two kind of antifungal drugs during the course of treatment